Trump Administration Announces 'Most-Favored-Nation' Drug Pricing Deals with Nine Firms

President Donald Trump on Monday announced drug pricing agreements with nine pharmaceutical companies aimed at lowering costs for state Medicaid programs. The deals are based on a most-favored-nation pricing model, which ties U.S. prices to those paid in other developed countries.

Details of the Agreements

The agreements were formalized during an Oval Office event with company executives. Under the terms, the firms will provide drugs to state Medicaid programs at what the administration described as a significant discount. President Trump stated this represents "a tremendous discount, which should bring down the cost of your medical care by tremendous amounts."

According to the announcement, the companies involved in the new agreements include:

• Astellas (TYO:4503)
• BeOne Medicines (SHH:688235)
• CSL (ASX:CSL)
• BridgeBIO (NASDAQ:BBIO)
• Sun Pharmaceutical (NSE:SUN)
• Teva (TASE:TEVA)
• UCB SA (EBR:UCB)

Context and Background

Ad

This initiative is part of a broader administration effort to tackle high prescription drug costs in the United States, where consumers pay, on average, nearly three times more for medicines than patients in other developed nations. The most-favored-nation pricing model is designed to compel drugmakers to offer prices in the U.S. that are comparable to lower prices paid internationally.

The new deals expand upon a program started last year, which secured similar agreements with 17 other major pharmaceutical companies, including Pfizer (NYSE:PFE), Eli Lilly (NYSE:LLY), and Amgen (NASDAQ:AMGN). Those arrangements involved price reductions for certain federal health programs and direct-to-patient sales in exchange for tariff relief, according to reports.

Implications for the Sector

For the participating companies, these agreements are likely to put downward pressure on revenues and profit margins from sales within the large U.S. Medicaid market. The full financial impact will depend on the specific drugs and discount levels negotiated.

Investors and the broader pharmaceutical industry will be closely monitoring whether this pricing model is extended to other government programs, such as Medicare, or if it influences future pricing negotiations with commercial insurers. The continued political focus on drug pricing remains a key consideration and potential risk factor for the healthcare sector.